Human studies using synthetic cannabinoids are rare in the context of patients with depression and anxiety [108,128]. Depression and anxiety in most of these studies were evaluated only as secondary analyses within healthy populations or populations suffering from another illness such as pain, cancer, and PTSD [5,108,128,178]. Nabilone (Cesamet) and dronabinol, synthetic analogues of THC, are two FDA cannabinoids approved and used to treat different ailments, including nausea and vomiting, associated with cancer chemotherapy and the treatment of anorexia associated with weight loss in patients with AIDS as well as multiple sclerosis (MS) in different countries [108]. In relation to depression and anxiety, nabilone improved the quality of life and reduced pain in a randomized, double-blind, placebo-controlled trial in patients with fibromyalgia [211], and reduced anxiety and pain in cancer patients when used as an adjunct to opioid treatment [212]. These data are in line with results obtained in studies using dronabinol, another synthetic THC, in patients with chronic central neuropathic pain or fibromyalgia [5,213,214]. Dronabinol has been studied in healthy populations in a small double-blind randomized controlled trial (RCT)
